Patterns of Use for GLP-1 Receptor Agonists in a Weight Management Cohort: A Military Health System Database Analysis of Active Duty Service Members From 2021 to 2025
Clicks: 1
ID: 320224
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #71 of 72 articles by views in Military Medicine
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Introduction Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for weight management, but real-world data on long-term persistence are crucial for understanding their effectiveness. This study aimed to compare persistence, adherence, and predictors of discontinuation among new users of different GLP-1RAs in the Military Health System (MHS). Materials and Methods This is a retrospective cohort study of 10,649 active duty service members (ADSMs) who initiated therapy with liraglutide (Saxenda), semaglutide (Wegovy), or tirzepatide (Zepbound) between January 1, 2021, and December 31, 2025. Persistence was defined as the time to the first gap in therapy exceeding 90 days. We used Kaplan-Meier survival analysis to estimate persistence rates and a multivariable Cox proportional hazards model to identify predictors of discontinuation. Results Significant differences in treatment outcomes were observed across all agents. Patients initiating Zepbound demonstrated the highest mean yearly adherence (proportion of days covered [PDC]: 78.2%), followed by Wegovy (71.6%), and Saxenda (48.7%). One-year persistence was highest for Zepbound (81.9%) and Wegovy (70.7%), and significantly lower for Saxenda (34.2%) (log-rank P < .001). In the adjusted Cox model, compared to Wegovy, the hazard of discontinuation was 33% lower for Zepbound (hazard ratio [HR]: 0.67, 95% confidence interval [CI]: 0.61-0.74) and 26% higher for Saxenda (HR: 1.26, 95% CI: 1.01-1.16). Male service members also had a significantly higher hazard of discontinuation compared to females (HR: 1.12, 95% CI: 1.02-1.22). Conclusions In this large cohort of ADSMs, Zepbound and Wegovy were associated with substantially higher persistence and adherence compared to Saxenda. These findings have important implications for clinical decision-making and formulary management to optimize long-term outcomes for weight management.
| Reference Key |
openalex_W7167811962
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Luke B Miller, Matthew J Dellen, E. Gilbert, Byron J. Faler, Joel R. Brockmeyer, J.J. Mandia |
| Journal | Military Medicine |
| Year | 2026 |
| DOI |
10.1093/milmed/usag316
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.